We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 18, 2021

Dapagliflozin Cost-Effectiveness in High-Risk T2D Patients

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
The Cost-Effectiveness of Dapagliflozin in Treating High-Risk Patients With Type 2 Diabetes Mellitus: An Economic Evaluation Using Data From the DECLARE-TIMI 58 Trial
Diabetes Obes Metab 2020 Dec 28;[EPub Ahead of Print], P McEwan, AR Morgan, R Boyce, K Bergenheim, IAM Gause-Nilsson, DL Bhatt, LA Leiter, PA Johansson, O Mosenzon, A Cahn, JPH Wilding

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading